semustine has been researched along with Multiple Myeloma in 4 studies
Semustine: 4-Methyl derivative of LOMUSTINE; (CCNU). An antineoplastic agent which functions as an alkylating agent.
semustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-methylcyclohexyl group.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized study with 234 previously untreated patients with multiple myeloma, 129 were treated with melphalan (8 mg/m2 perorally for four days) and prednisone (40 mg/m2 perorally for seven days, both every four weeks) and 105 with melphalan and prednisone at the same doses plus cyclophosphamide (600 mg/m2 intravenously every four weeks), MeCCNU (100 mg/m2 PO every eight weeks), and vincristine (MPCCV, 0." | 9.05 | A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma. ( Curuchet, M; Dragosky, M; Garay, G; Huberman, AB; Lein, JM; Palmer, L; Pavlovsky, S; Quiroga-Micheo, E; Saslavsky, J; Tezanos Pinto, M, 1984) |
| "Of 139 evaluable and previously untreated patients with multiple myeloma, 67 received methyl-CCNU-cyclophosphamide-prednisone (group A) and 72 received melphalan-prednisone (group B); 48% and 33% respectively had good responses and the overall response rates (good plus partial) were 75% and 65% for groups A and B respectively." | 9.05 | Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. ( Becherini, JO; Cavagnaro, F; Jait, C; Lein, JM; Micheo, EQ; Musso, A; Pavlovsky, S; Pileggi, JE; Pizzolato, M; Suárez, A, 1980) |
| "Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper." | 9.04 | Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma. ( Silberman, H; Solomon, A; Tornyos, K, 1977) |
| "In a randomized study with 234 previously untreated patients with multiple myeloma, 129 were treated with melphalan (8 mg/m2 perorally for four days) and prednisone (40 mg/m2 perorally for seven days, both every four weeks) and 105 with melphalan and prednisone at the same doses plus cyclophosphamide (600 mg/m2 intravenously every four weeks), MeCCNU (100 mg/m2 PO every eight weeks), and vincristine (MPCCV, 0." | 5.05 | A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma. ( Curuchet, M; Dragosky, M; Garay, G; Huberman, AB; Lein, JM; Palmer, L; Pavlovsky, S; Quiroga-Micheo, E; Saslavsky, J; Tezanos Pinto, M, 1984) |
| "Of 139 evaluable and previously untreated patients with multiple myeloma, 67 received methyl-CCNU-cyclophosphamide-prednisone (group A) and 72 received melphalan-prednisone (group B); 48% and 33% respectively had good responses and the overall response rates (good plus partial) were 75% and 65% for groups A and B respectively." | 5.05 | Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. ( Becherini, JO; Cavagnaro, F; Jait, C; Lein, JM; Micheo, EQ; Musso, A; Pavlovsky, S; Pileggi, JE; Pizzolato, M; Suárez, A, 1980) |
| "Thirteen patients with multiple myeloma (MM) who either failed to respond to or who were relapsing from standard agents and who received four or more courses of methyl-CCNU + prednisone (adequate drug trial) are reported in this paper." | 5.04 | Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma. ( Silberman, H; Solomon, A; Tornyos, K, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pavlovsky, S | 2 |
| Saslavsky, J | 1 |
| Tezanos Pinto, M | 1 |
| Palmer, L | 1 |
| Curuchet, M | 1 |
| Lein, JM | 2 |
| Garay, G | 1 |
| Dragosky, M | 1 |
| Quiroga-Micheo, E | 1 |
| Huberman, AB | 1 |
| Cavagnaro, F | 1 |
| Becherini, JO | 1 |
| Pileggi, JE | 1 |
| Micheo, EQ | 1 |
| Jait, C | 1 |
| Musso, A | 1 |
| Suárez, A | 1 |
| Pizzolato, M | 1 |
| Tornyos, K | 1 |
| Silberman, H | 1 |
| Solomon, A | 1 |
| Dhingra, K | 1 |
4 trials available for semustine and Multiple Myeloma
| Article | Year |
|---|---|
A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Clinical Trials as Topic; Cyclophosp | 1984 |
Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combin | 1980 |
Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Alkylating Agents; Clinical Trials as Topic; Drug Resistance; Dru | 1977 |
Treatment of multiple myeloma: an Argentine Group for the Treatment of Acute Leukemia Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Clinical Trials as Topic; Cyclophosphamid | 1988 |